Profile data is unavailable for this security.
About the company
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
- Revenue in USD (TTM)0.00
- Net income in USD-190.42m
- Incorporated2013
- Employees112.00
- LocationAllovir Inc1100 Winter StreetWALTHAM 02451United StatesUSA
- Phone+1 (617) 433-2605
- Fax+1 (302) 655-5049
- Websitehttps://www.allovir.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Teknova Inc | 36.68m | -36.78m | 82.06m | 210.00 | -- | 0.9107 | -- | 2.24 | -1.17 | -1.17 | 1.15 | 2.21 | 0.2612 | 2.21 | 8.94 | 174,685.70 | -26.19 | -- | -28.17 | -- | 28.07 | -- | -100.26 | -- | 3.84 | -37.45 | 0.1283 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Atara Biotherapeutics Inc | 8.57m | -276.13m | 82.56m | 225.00 | -- | -- | -- | 9.63 | -2.61 | -2.61 | 0.0810 | -0.9322 | 0.0316 | 1.57 | 0.2307 | 38,102.22 | -101.91 | -70.20 | -172.16 | -86.94 | -3.65 | -- | -3,220.88 | -1,559.33 | 0.648 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Chimerix Inc | 324.00k | -82.10m | 83.17m | 72.00 | -- | 0.4295 | -- | 256.70 | -0.9267 | -0.9267 | 0.0037 | 2.17 | 0.0013 | -- | 0.6207 | 4,500.00 | -33.36 | -30.45 | -36.22 | -34.09 | 100.00 | -- | -25,337.96 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -68.96m | 83.34m | 63.00 | -- | 0.3693 | -- | -- | -1.44 | -1.44 | 0.00 | 4.39 | 0.00 | -- | -- | 0.00 | -26.40 | -21.16 | -27.72 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Connect Biopharma Holdings Ltd (ADR) | -100.00bn | -100.00bn | 83.71m | 100.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 39.01 | -- | -- | -- |
| Angion Biomedica Corp | 0.00 | -35.19m | 84.24m | 32.00 | -- | 6.95 | -- | -- | -8.81 | -8.81 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -88.05 | -105.91 | -110.32 | -331.69 | -- | -- | -- | -712.81 | -- | -700.88 | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 84.31m | 10.00 | -- | 14.74 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | -- | -184.22 | -- | -404.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Allovir Inc | 0.00 | -190.42m | 84.65m | 112.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -52.85 | -- | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | -- | -- | -- | -- | -12.87 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -12.94m | 84.86m | 6.00 | -- | 2.03 | -- | -- | -2.85 | -2.85 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -64.61 | -85.29 | -76.36 | -100.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.45 | -- | -- | -- |
| BioXcel Therapeutics Inc | 1.38m | -179.05m | 85.26m | 74.00 | -- | -- | -- | 61.78 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -37.34m | 85.53m | 16.00 | -- | -- | -- | -- | -1.37 | -1.37 | 0.00 | -0.2482 | 0.00 | -- | -- | 0.00 | -274.94 | -111.48 | -- | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | -- | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| LifeVantage Corp | 210.95m | 2.96m | 85.70m | 248.00 | 28.72 | 3.14 | 12.96 | 0.4063 | 0.2319 | 0.2319 | 16.51 | 2.12 | 3.23 | 2.43 | 88.97 | 850,604.80 | 4.54 | 11.65 | 7.04 | 18.92 | 79.65 | 82.20 | 1.40 | 3.42 | 1.03 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
| Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 86.63m | 47.00 | -- | 3.25 | -- | 86.63 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Aclaris Therapeutics Inc | 31.25m | -88.48m | 87.24m | 91.00 | -- | 0.5548 | -- | 2.79 | -1.27 | -1.27 | 0.4477 | 2.22 | 0.1383 | -- | 79.92 | 343,395.60 | -39.15 | -47.29 | -44.34 | -53.87 | 42.14 | 44.00 | -283.15 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Data as of Apr 19 2024. Currency figures normalised to Allovir Inc's reporting currency: US Dollar USD
37.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 22 Jan 2024 | 10.66m | 9.34% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 6.60m | 5.78% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.69m | 4.99% |
| Millennium Management LLCas of 31 Dec 2023 | 3.90m | 3.42% |
| Wasatch Advisors, Inc.as of 31 Dec 2023 | 3.78m | 3.32% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.25m | 2.85% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.90m | 2.54% |
| Woodline Partners LPas of 31 Dec 2023 | 2.51m | 2.20% |
| Redmile Group LLCas of 31 Dec 2023 | 1.91m | 1.67% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.25m | 1.10% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
